Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients ...

Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight The non-small cell lung cancer clinical trial analysis report ...

The advent of mRNA vaccines against SARS-CoV-2 in 2020 changed the course of the COVID-19 pandemic. Now, the Nobel ...

First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant ...

Researchers have developed a pathology tool powered by AI that can predict whether a patient with extensive-stage small cell ...

Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above ...

Zongertinib in phase I trial showed sustained efficacy in aggressive disease ...

Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Phase Ib/II clinical trial to explore ...

Learn how G-CSF and trilaciclib help prevent febrile neutropenia in extensive-stage SCLC, with NCCN-backed timing tips and ...

The BRAF-mutated NSCLC market is poised for growth due to an increasing incidence rate across 7MM. Currently, only one approved therapy, the Tafinlar and Mekinist combo, targets this mutation.

Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).

The Lung Cancer Research Foundation (LCRF) announces the first recipients of its LCRF Team Science Award on Advancing Therapies Toward Curing EGFR Mutated Lung Cancers. The project, "A novel ...